Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

6 treatments under study, led by Arthemeterlumefantrine

Research Leaders

5 sponsors active, led by National Institute of Malariology, Parasitology and Entomology, Vietnam

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

100%

2 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Phase 3 (1)
Phase 4 (1)

Trial Status

Unknown1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT02974348Phase 3CompletedPrimary

Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa

NCT02604966Phase 4UnknownPrimary

P. Falciparum Resistance to Artemisinin in Vietnam

Showing all 2 trials

Research Network

Common Treatments

  • Arthemeterlumefantrine1
  • Acetaminophen1
  • Dha Ppq Group1
  • Artesunate Mefloquine1
  • Dihydroartemisinin Piperaquine1

Active Sponsors

  • National Institute of Malariology, Parasitology and Entomology, Vietnam1
  • Institute of Tropical Medicine, Belgium1
  • University of Bamenda1
  • Ministry of Science and Technology of the People´s Republic of China1
  • National Institute for Parasitic Disease, Chinese Center for Disease Control and Prevention1

Top Investigators

Activity Timeline